Articles tagged with Sars Cov 2
A recent survey of NYC residents found that nearly 3 in 10 reported losing their jobs due to coronavirus. Additionally, 80% experienced reduced ability to get food they need, and two-thirds lost social connections. The findings highlight disproportionate impacts on Hispanics, lower-income city residents, and middle-aged respondents.
The article provides guidance on supporting clinicians during the COVID-19 pandemic. Key findings highlight the importance of maintaining a patient-centered approach and adapting to new clinical challenges.
Researchers at Helmholtz-Zentrum Berlin have decoded the 3D architecture of the SARS-CoV-2 main protease, providing concrete starting points for developing inhibitors. The analysis was conducted using high-intensity X-ray light from BESSY II.
Researchers analyzed public genome sequence data to determine the origins of SARS-CoV-2. They found no evidence that the virus was engineered or created in a laboratory, supporting natural evolution as its origin.
The study found SARS-CoV-2 stable in aerosols for up to three hours and on copper for up to four hours, while also detectable for 24 hours on cardboard and two to three days on plastic and stainless steel. This stability suggests people may acquire the virus through air and after touching contaminated objects.
The National Institute of Allergy and Infectious Diseases has begun a Phase 1 clinical trial for an investigational COVID-19 vaccine in the Seattle area. The trial is evaluating different doses of the mRNA-1273 vaccine for safety and immune response in healthy adult volunteers.
A review of COVID-19 infections in children reveals milder symptoms and lower risk of severe disease compared to adults. Children account for only two percent of hospitalizations and most recover within one to two weeks after symptom onset.
Researchers analyzed lung tissue from a COVID-19 patient to investigate histopathologic changes and SARS-CoV-2 immunostaining. The study found distinct patterns of immune cell activation and inflammation, shedding light on the disease's pathophysiology.
Researchers analyzed published scientific data on SARS-CoV-2 and related coronaviruses to identify potential therapeutic agents and vaccines. More than 500 patents have been issued for COVID-19 treatments, including antibodies and nucleic acids.
A study published in The Lancet describes the first locally-transmitted case of SARS-CoV-2 in the USA, where a woman transmitted the virus to her husband after returning from China. Despite extensive contact tracing and monitoring, no further transmission was detected.
Researchers used existing data from known coronaviruses to predict which parts of SARS-CoV-2 are capable of activating the human immune system. The study identified five regions in the spike glycoprotein, membrane protein, and nucleoprotein that elicit a strong immune response.
Researchers estimate the median incubation period of COVID-19 to be 5.1 days, with 97.5% of cases developing symptoms within 11.5 days of infection. This supports current CDC recommendations for active monitoring and quarantine.
Researchers found that SARS-CoV-2 requires the protease TMPRSS2 to enter host cells, a target for therapeutic intervention. The drug camostat mesilate, approved for pancreatic inflammation, shows promise in blocking virus entry into lung cells.
A team of HKUST scientists has identified potential vaccine targets for SARS-CoV-2, leveraging genetic similarity with SARS-CoV. The study found that only 20% of SARS-CoV epitopes map identically to SARS-CoV-2, but these promising candidates may offer protection against COVID-19.
Four research teams at Columbia University will pursue four different approaches to develop drugs and antibodies against the new coronavirus. They aim to identify protease inhibitors, polymerase inhibitors, and monoclonal antibodies, with the goal of advancing at least one compound into clinical trials within a year.
Researchers describe key chest CT imaging findings in Wuhan coronavirus patients, highlighting bilateral ground-glass and consolidative pulmonary opacities. The study's findings suggest that lung cavitation, discrete nodules, and lymphadenopathy are characteristically absent in cases of 2019-nCoV.
A new modelling study estimates that up to 75,800 individuals in Wuhan may have been infected with 2019-nCoV by January 25, 2020. The researchers also suggest that multiple major Chinese cities might have already imported dozens of cases of 2019-nCoV infection from Wuhan.
The Lancet report provides comprehensive clinical and treatment data on 2019-nCoV cases from Wuhan, China. Most patients had underlying chronic diseases and pneumonia, but responded well to antivirals and antibiotics.
The 2019-nCoV virus has nearly identical genetic sequences among patients, indicating a recent emergence and rapid detection. The virus shares similarities with bat-derived coronaviruses and may use the ACE2 receptor to enter human cells.
The emergence of a new coronavirus from animals to humans poses a significant threat, prompting the need for swift action. Researchers are developing diagnostic tests, exploring broad-spectrum anti-viral drugs, and adapting approaches used with earlier outbreaks to jumpstart candidate vaccine development.
A new study reveals that the 2019-nCoV coronavirus likely originated from a combination of a bat coronavirus and an unknown coronavirus, with recombination allowing cross-species transmission to humans via snakes. This finding highlights the importance of understanding viral origins for effective control of emerging outbreaks.